Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dobutamine + norepinephrine is a combination of two intravenous cardiovascular agents commonly used together in critical care settings, particularly for the management of shock states such as septic shock or cardiogenic shock. Dobutamine is an inotropic agent that primarily stimulates beta-1 adrenergic receptors, increasing myocardial contractility and cardiac output with relatively mild effects on heart rate and vasodilation. Norepinephrine acts mainly as a potent vasoconstrictor by stimulating alpha-adrenergic receptors, thereby increasing systemic vascular resistance and blood pressure. The combination is used when patients require both increased cardiac output (from dobutamine) and improved vascular tone/blood pressure (from norepinephrine), especially when single-agent therapy is insufficient to achieve hemodynamic goals[1][7][9]. This regimen does not exist as a fixed-dose pharmaceutical product but rather involves co-administration of the two drugs via separate infusions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dobutamine + norepinephrine.